|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ZDHHC12 |
Gene summary for ZDHHC12 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ZDHHC12 | Gene ID | 84885 |
| Gene name | zinc finger DHHC-type palmitoyltransferase 12 | |
| Gene Alias | DHHC-12 | |
| Cytomap | 9q34.11 | |
| Gene Type | protein-coding | GO ID | GO:0006464 | UniProtAcc | Q96GR4 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 84885 | ZDHHC12 | LZE2T | Human | Esophagus | ESCC | 1.27e-04 | 4.10e-01 | 0.082 |
| 84885 | ZDHHC12 | LZE4T | Human | Esophagus | ESCC | 3.51e-17 | 5.10e-01 | 0.0811 |
| 84885 | ZDHHC12 | LZE5T | Human | Esophagus | ESCC | 2.57e-02 | 1.18e-01 | 0.0514 |
| 84885 | ZDHHC12 | LZE7T | Human | Esophagus | ESCC | 2.12e-06 | 5.94e-01 | 0.0667 |
| 84885 | ZDHHC12 | LZE8T | Human | Esophagus | ESCC | 3.95e-11 | 1.71e-01 | 0.067 |
| 84885 | ZDHHC12 | LZE20T | Human | Esophagus | ESCC | 2.42e-16 | 6.95e-01 | 0.0662 |
| 84885 | ZDHHC12 | LZE22D1 | Human | Esophagus | HGIN | 6.10e-04 | 2.89e-01 | 0.0595 |
| 84885 | ZDHHC12 | LZE22T | Human | Esophagus | ESCC | 2.24e-02 | 5.25e-01 | 0.068 |
| 84885 | ZDHHC12 | LZE24T | Human | Esophagus | ESCC | 2.67e-26 | 8.18e-01 | 0.0596 |
| 84885 | ZDHHC12 | LZE21T | Human | Esophagus | ESCC | 2.45e-03 | 5.87e-01 | 0.0655 |
| 84885 | ZDHHC12 | LZE6T | Human | Esophagus | ESCC | 5.47e-08 | 5.69e-01 | 0.0845 |
| 84885 | ZDHHC12 | P1T-E | Human | Esophagus | ESCC | 4.73e-13 | 5.79e-01 | 0.0875 |
| 84885 | ZDHHC12 | P2T-E | Human | Esophagus | ESCC | 7.34e-23 | 5.28e-01 | 0.1177 |
| 84885 | ZDHHC12 | P4T-E | Human | Esophagus | ESCC | 8.00e-26 | 6.94e-01 | 0.1323 |
| 84885 | ZDHHC12 | P5T-E | Human | Esophagus | ESCC | 7.19e-24 | 6.00e-01 | 0.1327 |
| 84885 | ZDHHC12 | P8T-E | Human | Esophagus | ESCC | 1.08e-58 | 1.22e+00 | 0.0889 |
| 84885 | ZDHHC12 | P9T-E | Human | Esophagus | ESCC | 1.44e-25 | 6.99e-01 | 0.1131 |
| 84885 | ZDHHC12 | P10T-E | Human | Esophagus | ESCC | 2.12e-18 | 4.37e-01 | 0.116 |
| 84885 | ZDHHC12 | P11T-E | Human | Esophagus | ESCC | 1.44e-20 | 9.38e-01 | 0.1426 |
| 84885 | ZDHHC12 | P12T-E | Human | Esophagus | ESCC | 8.86e-21 | 2.97e-01 | 0.1122 |
| Page: 1 2 3 4 5 6 7 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000660525 | Esophagus | HGIN | protein targeting | 78/2587 | 314/18723 | 1.08e-07 | 5.47e-06 | 78 |
| GO:009015020 | Esophagus | HGIN | establishment of protein localization to membrane | 67/2587 | 260/18723 | 1.96e-07 | 9.57e-06 | 67 |
| GO:00435435 | Esophagus | HGIN | protein acylation | 51/2587 | 243/18723 | 1.33e-03 | 1.57e-02 | 51 |
| GO:0006605111 | Esophagus | ESCC | protein targeting | 229/8552 | 314/18723 | 4.93e-23 | 1.01e-20 | 229 |
| GO:0090150110 | Esophagus | ESCC | establishment of protein localization to membrane | 182/8552 | 260/18723 | 1.27e-15 | 8.19e-14 | 182 |
| GO:004354313 | Esophagus | ESCC | protein acylation | 165/8552 | 243/18723 | 1.69e-12 | 7.14e-11 | 165 |
| GO:00421573 | Esophagus | ESCC | lipoprotein metabolic process | 86/8552 | 135/18723 | 1.78e-05 | 1.57e-04 | 86 |
| GO:00064973 | Esophagus | ESCC | protein lipidation | 62/8552 | 92/18723 | 2.08e-05 | 1.80e-04 | 62 |
| GO:00421583 | Esophagus | ESCC | lipoprotein biosynthetic process | 64/8552 | 96/18723 | 2.61e-05 | 2.20e-04 | 64 |
| GO:00066124 | Esophagus | ESCC | protein targeting to membrane | 83/8552 | 131/18723 | 3.31e-05 | 2.73e-04 | 83 |
| GO:003432918 | Esophagus | ESCC | cell junction assembly | 227/8552 | 420/18723 | 3.06e-04 | 1.83e-03 | 227 |
| GO:00066057 | Liver | Cirrhotic | protein targeting | 148/4634 | 314/18723 | 3.86e-18 | 6.20e-16 | 148 |
| GO:00901507 | Liver | Cirrhotic | establishment of protein localization to membrane | 123/4634 | 260/18723 | 1.85e-15 | 2.15e-13 | 123 |
| GO:00435431 | Liver | Cirrhotic | protein acylation | 95/4634 | 243/18723 | 4.73e-07 | 1.07e-05 | 95 |
| GO:00066122 | Liver | Cirrhotic | protein targeting to membrane | 53/4634 | 131/18723 | 5.17e-05 | 5.95e-04 | 53 |
| GO:0042157 | Liver | Cirrhotic | lipoprotein metabolic process | 53/4634 | 135/18723 | 1.32e-04 | 1.29e-03 | 53 |
| GO:0042158 | Liver | Cirrhotic | lipoprotein biosynthetic process | 36/4634 | 96/18723 | 3.69e-03 | 2.03e-02 | 36 |
| GO:0006497 | Liver | Cirrhotic | protein lipidation | 33/4634 | 92/18723 | 1.12e-02 | 4.92e-02 | 33 |
| GO:000660512 | Liver | HCC | protein targeting | 219/7958 | 314/18723 | 7.74e-23 | 1.49e-20 | 219 |
| GO:009015012 | Liver | HCC | establishment of protein localization to membrane | 168/7958 | 260/18723 | 4.07e-13 | 2.13e-11 | 168 |
| Page: 1 2 3 4 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ZDHHC12 | SNV | Missense_Mutation | c.94N>C | p.Asp32His | p.D32H | Q96GR4 | protein_coding | deleterious(0.01) | possibly_damaging(0.752) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| ZDHHC12 | insertion | In_Frame_Ins | novel | c.343_344insGAGGGGGAAGGGACACACTTTGCCCAGTGACACTGAGCA | p.Glu115delinsGlyGlyGlyArgAspThrLeuCysProValThrLeuSerLys | p.E115delinsGGGRDTLCPVTLSK | Q96GR4 | protein_coding | TCGA-AN-A0FX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| ZDHHC12 | SNV | Missense_Mutation | novel | c.676N>T | p.Arg226Cys | p.R226C | Q96GR4 | protein_coding | tolerated(0.08) | benign(0.003) | TCGA-MA-AA41-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| ZDHHC12 | SNV | Missense_Mutation | rs373582038 | c.187N>A | p.Ala63Thr | p.A63T | Q96GR4 | protein_coding | tolerated(0.4) | possibly_damaging(0.807) | TCGA-D5-6928-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| ZDHHC12 | SNV | Missense_Mutation | c.514N>A | p.Gln172Lys | p.Q172K | Q96GR4 | protein_coding | tolerated(0.92) | benign(0.007) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| ZDHHC12 | SNV | Missense_Mutation | rs754548655 | c.410N>A | p.Arg137His | p.R137H | Q96GR4 | protein_coding | deleterious(0) | probably_damaging(0.947) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
| ZDHHC12 | SNV | Missense_Mutation | novel | c.661N>A | p.Ala221Thr | p.A221T | Q96GR4 | protein_coding | tolerated(0.16) | benign(0.007) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |
| ZDHHC12 | SNV | Missense_Mutation | novel | c.655N>A | p.Arg219Ser | p.R219S | Q96GR4 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-B5-A1MX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Hormone Therapy | megace | SD |
| ZDHHC12 | SNV | Missense_Mutation | rs779093383 | c.524G>A | p.Arg175Gln | p.R175Q | Q96GR4 | protein_coding | tolerated(0.44) | benign(0.017) | TCGA-B5-A3FC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| ZDHHC12 | SNV | Missense_Mutation | novel | c.430N>A | p.Val144Ile | p.V144I | Q96GR4 | protein_coding | tolerated(0.39) | benign(0.01) | TCGA-DF-A2KU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |